INTRODUCTION
Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed for the treatment of a variety of psychiatric disorders, such as depression,1,2 bipolar affective disorder,3 anxiety-related disorders (obsessive compulsive disorder, post-traumatic stress disorder),4,5 aggression6 and autism spectrum disorder.7,8 All these disorders have symptoms related to, among others, negative affectivity, which might be the symptom responsive to SSRI treatment. Clinical studies have shown that there are many side effects upon chronic administration of SSRIs, like sexual dysfunction,9 suppression of rapid eye movement sleep,10 nausea,11,12 decreased appetite13 and deterioration of symptoms (for example, aggression).14,15 indicating that optimization of chronic treatment of affective disorders is needed. In addition, some patients remain free of symptoms after discontinuation of SSRI treatment, whereas in others the symptoms recur.16,17 Studies in generalized social anxiety disorder patients showed that within 24 weeks after discontinuation of SSRI treatment 40–50% of the patients (receiving placebo after stopping SSRI) relapsed.18,19 For major depressive disorder, the cumulative probability of suffering a recurrence of major depression within 2 years after discontinuation of SSRIs was 60% for people aged 60 years or older.20 Hence, the effects of SSRIs are not always sufficient to warrant long-term remission. To further improve the efficacy of SSRIs, there is an urgent need to unravel the mechanisms contributing to the long-term effects of chronic SSRI exposure.

The primary target of SSRIs is the serotonin transporter (5-HTT); its blockade by SSRIs leads to increases in extracellular serotonin (5-HT) levels. According to classic literature, chronic rises in 5-HT levels would contribute to the therapeutic effects of SSRIs,21 acting through 5-HT receptors. For example, antagonism of 5-HT2C and 5-HT7 results in significantly increased therapeutic effects of SSRIs.22–25 and SSRI/5-HT1A antagonist co-administration leads to increased extracellular 5-HT levels and enhanced antidepressant responses.26,27 However, these and other 5-HT receptors are also implicated in the side effects of SSRIs, like sexual dysfunction (5-HT1A),28 sleep disturbances (5-HT7,29 5-HT1A30), nausea (5-HT3B31) and decreased appetite (5-HT2C32 5-HT1B33). Although 5-HT receptors have a key role in the short-term effects of chronic SSRI exposure, it is likely that pathways downstream of the receptors are important for the long-term effects of chronic SSRI exposure.

Recently, several gene expression studies in rodents have shown that SSRI exposure can affect a wide variety of pathways in addition to the serotonergic system. It has been shown that SSRI treatment during adulthood alters gene expression levels of hypothalamic hormones, neurotrophic factors, inflammatory factors and components of non-serotonergic neurotransmitter pathways.29,34,35 Therefore, it is possible that SSRI exposure alters the expression of genes involved in myelination, leading to long-term changes in expression of these genes after discontinuation of SSRI treatment. Here we aimed to study the effects of chronic SSRI exposure on the expression of genes involved in myelination-related processes, which might be the target responsive to SSRI treatment. Clinical studies have shown that there are many side effects upon chronic administration of SSRIs, like sexual dysfunction,9 suppression of rapid eye movement sleep,10 nausea,11,12 decreased appetite13 and deterioration of symptoms (for example, aggression).14,15 indicating that optimization of chronic treatment of affective disorders is needed. In addition, some patients remain free of symptoms after discontinuation of SSRI treatment, whereas in others the symptoms recur.16,17 Studies in generalized social anxiety disorder patients showed that within 24 weeks after discontinuation of SSRI treatment 40–50% of the patients (receiving placebo after stopping SSRI) relapsed.18,19 For major depressive disorder, the cumulative probability of suffering a recurrence of major depression within 2 years after discontinuation of SSRIs was 60% for people aged 60 years or older.20 Hence, the effects of SSRIs are not always sufficient to warrant long-term remission. To further improve the efficacy of SSRIs, there is an urgent need to unravel the mechanisms contributing to the long-term effects of chronic SSRI exposure.

The primary target of SSRIs is the serotonin transporter (5-HTT); its blockade by SSRIs leads to increases in extracellular serotonin (5-HT) levels. According to classic literature, chronic rises in 5-HT levels would contribute to the therapeutic effects of SSRIs,21 acting through 5-HT receptors. For example, antagonism of 5-HT2C and 5-HT7 results in significantly increased therapeutic effects of SSRIs.22–25 and SSRI/5-HT1A antagonist co-administration leads to increased extracellular 5-HT levels and enhanced antidepressant responses.26,27 However, these and other 5-HT receptors are also implicated in the side effects of SSRIs, like sexual dysfunction (5-HT1A),28 sleep disturbances (5-HT7,29 5-HT1A30), nausea (5-HT3B31) and decreased appetite (5-HT2C32 5-HT1B33). Although 5-HT receptors have a key role in the short-term effects of chronic SSRI exposure, it is likely that pathways downstream of the receptors are important for the long-term effects of chronic SSRI exposure.

Recently, several gene expression studies in rodents have shown that SSRI exposure can affect a wide variety of pathways in addition to the serotonergic system. It has been shown that SSRI treatment during adulthood alters gene expression levels of hypothalamic hormones, neurotrophic factors, inflammatory factors and components of non-serotonergic neurotransmitter pathways.29,34,35 Therefore, it is possible that SSRI exposure alters the expression of genes involved in myelination, leading to long-term changes in expression of these genes after discontinuation of SSRI treatment. Here we aimed to study the effects of chronic SSRI exposure on the expression of genes involved in myelination-related processes, which might be the target responsive to SSRI treatment.
Especially the inflammatory factors might have a central role in mediating the effects of SSRIs, because down-regulation of proinflammatory cytokines can inhibit HPA axis function (facilitating stress reduction), enhance 5-HT and dopamine synthesis and inhibit 5-HT and dopamine reuptake. Yet, these findings reflect short-term effects (24 h after the last treatment) of chronic SSRI exposure. The long-term consequences of SSRI exposure on gene expression are so far not well understood and might provide additional information about the long-term adaptations that contribute to the remediation of disease symptoms after stopping medication.

Studies addressing the long-term consequences of perinatal SSRI exposure may provide hints regarding potential mechanisms by which SSRIs exert their long-term effects. In humans and rodents, there is evidence that perinatal SSRI exposure increases the likelihood of symptoms related to autism in the offspring. This seemingly contrasts the use of SSRIs in the treatment of autism during adulthood. In addition, in rodents perinatally exposed to SSRIs there is evidence for ‘paradoxical’ anxiety- and depression-like symptoms at adulthood. Because adult and perinatal SSRI exposure is associated with comparable effects on the serotonergic system, like increases in 5-HT levels, reductions in 5-HT transporter expression and desensitization of 5-HT1A receptors, the ‘paradoxical’ outcomes of perinatal SSRI exposure cannot be explained by 5-HT levels alone. Critically, during development, 5-HT not only acts as a neurotransmitter, but also as a neurotrophic factor. Specifically, during early brain development, 5-HT steers neurodevelopmental processes like neuronal outgrowth and migration processes. Studies have shown that 5-HT affects embryonic interneuron migration and also affects organization of axonal projections of excitatory spiny stellate and pyramidal cells in the barrel cortex. These data show that 5-HT affects the outgrowth and migration of non-serotonergic neurons. As the brain is highly plastic during early development, rises in 5-HT levels induced by perinatal SSRI exposure can have outcomes that are substantially different from adult SSRI exposure. Nonetheless, studies focusing on early-life SSRI exposure could lead to potential targets of the long-term chronic SSRI exposure during adulthood. For example, SSRI exposure during brain development can disturb myelin sheath formation at adulthood and there is also evidence that SSRI treatment at adulthood can cause changes in white matter microstructure, which consists mainly of myelinated axons. Furthermore, both adult and developmental SSRI exposure can affect hippocampal neurogenesis at adulthood.

To more concretely elucidate the long-term effects of chronic SSRI exposure during adulthood, we investigated the long-term consequences of chronic fluoxetine (12 mg kg−1) versus vehicle treatment during adulthood (postnatal day (PND) 67–88) on gene expression in the hippocampus, a brain region that is highly responsive to SSRIs and implicated in psychiatric disorders characterized by affective changes like anxiety, bipolar affective disorder, aggression and depression. It has, for example, been shown that the hippocampus is directly involved in the mediation of unconditioned anxiety-related responses in animals. We measured body weight during treatment, as fluoxetine is known to exert anorectic effects. In addition, we measured anxiety-like behavior in the novelty-suppressed feeding test (NSFT), which is highly sensitive to SSRIs. We studied genome-wide gene expression using transcriptome analysis (RNA-seq) in the hippocampal tissue of fluoxetine- and vehicle-exposed rats 40 days after the last treatment. Differentially regulated genes were validated by quantitative reverse transcription PCR (qRT-PCR) analysis using independent samples. Gene ontology analysis showed that the majority of upregulated genes had a function in myelination. To assess whether genes involved in myelination were also affected by early-life exposure to fluoxetine, we performed qPCR analysis on the genes involved in myelination in a group of rats neonatally exposed to fluoxetine or vehicle. Finally, we performed correlational analysis between anxiety-like behavior and messenger RNA (mRNA) expression.

**Materials and Methods**

**Animals**

Male Wistar rats (Rattus norvegicus) were obtained from Charles River (Cologne, Germany) and used for experiments after at least 7 days of acclimatization. All the animals were housed per two in standard Macrolon type 3 cages in temperature-controlled rooms (21°C ± 1°C) under a 12:12 h light–dark cycle. All experimental procedures were approved by the local Ethical Board of the University of Maastricht, The Netherlands.

**Experimental Design**

Male Wistar rats, group 1 (n = 12 per treatment) and 2 (n = 4 per treatment), were treated with fluoxetine or vehicle from postnatal day (PND) 67 to 88. During the treatment period, body weight was measured every day. In group 1, anxiety-like behavior was tested on PND 95 using the novelty-suppressed feeding test (NSFT). Groups 1 and 2 were killed by decapitation on PND 120 and PND 128, respectively and used for mRNA expression analysis using hippocampal tissue. Group 3 (fluoxetine n = 6, vehicle n = 7) was used to investigate the effect of chronic fluoxetine exposure on hippocampal mRNA expression in Sprague Dawley rats. For neonatal exposure, dams were treated during the postpartum period from PND 1 to 21. At PND 21, pups were weaned and group-housed for further examination (two rats per cage). Anxiety- and depression-related behavior was analyzed from PND 140 onwards (in the order as written in the figure) and the rats were killed by decapitation at PND 196. mRNA, messenger RNA; qPCR, quantitative PCR.

**Figure 1.** Schematic representation of experimental timeline. Male Wistar rats, group 1 (n = 12 per treatment) and 2 (n = 4 per treatment), were treated with fluoxetine or vehicle from postnatal day (PND) 67 to 88. During the treatment period, body weight was measured every day. In group 1, anxiety-like behavior was tested on PND 95 using the novelty-suppressed feeding test (NSFT). Groups 1 and 2 were killed by decapitation on PND 120 and PND 128, respectively and used for mRNA expression analysis using hippocampal tissue. Group 3 (fluoxetine n = 6, vehicle n = 7) was used to investigate the effect of chronic fluoxetine exposure on hippocampal mRNA expression in Sprague Dawley rats. For neonatal exposure, dams were treated during the postpartum period from PND 1 to 21. At PND 21, pups were weaned and group-housed for further examination (two rats per cage). Anxiety- and depression-related behavior was analyzed from PND 140 onwards (in the order as written in the figure) and the rats were killed by decapitation at PND 196. mRNA, messenger RNA; qPCR, quantitative PCR.
standard 12/12-h day/night cycle (lights on at 0700 h) with food (Sniff, long-cut pellet, Bio Services, Uden, The Netherlands) and water available ad libitum. Environmental conditions (for example, housing, light conditions (80 lux), noise level) were carefully controlled as these conditions can strongly influence stress levels in rats.47,48 Three groups of animals were used in this study. In each group, the rats were randomly assigned to a treatment. The investigator was not blinded to the group allocations when performing the experiments, because effects of fluoxetine on the body weight and behavior were clearly visible. Group 1 was treated at adulthood with fluoxetine or vehicle (n = 12 per treatment), used for body weight measurements during treatment, tested in the NSFT and decapitated to collect hippocampal tissue for qRT-PCR validation; group 2 was treated at adulthood with fluoxetine or vehicle (n = 4 per treatment) and used for RNA-seq experiments. Finally, group 3 consisted of adult female Sprague Dawley rats neonatally exposed to fluoxetine or vehicle (PND 1 to 21) via osmotic minipumps implanted in the mothers. Their hippocampal tissue was obtained from Maastricht University (fluoxetine n = 6, vehicle n = 7) and used for qPCR analysis. Figure 1 provides a schematic representation of the experimental timeline for each group. For behavior experiments, 12 animals per group were used, because this is the minimum required to achieve sufficient statistical power to establish significant differences (α = 0.05 and β = 0.20). For genome-wide gene expression analysis, we used two biological replicates. All the experiments were carried out according to the guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (National Research Council 2003), the principles of laboratory animal care, as well as the Dutch law concerning animal welfare.

Drug treatment
Rats from group 1 and 2 received fluoxetine (12 mg kg\(^{-1}\) per day, as used by Olivier et al.47) or vehicle by oral gavage from PND 67 to 88 in a volume of 5 ml kg\(^{-1}\). Fluoxetine was purchased from the Pharmacy of the Radboud University Nijmegen Medical Centre, The Netherlands and dissolved in distilled water. As a vehicle, 1% methylcellulose (Genfarma, Maarssen, The Netherlands) was used, which was the constituent of the fluoxetine pills. Body weight was monitored daily throughout the treatment. Rats from group 3 received fluoxetine via the milk of the dams. Minipumps were implanted subcutaneously in the dorsal region of the dams on PND 1 and filled with either fluoxetine–HCl (Fagron, Waregem, Belgium) dissolved in vehicle (50% propylene glycol in saline; 5 mg kg\(^{-1}\) per day), or with vehicle, as previously described.49

Novelty-suppressed feeding test
The NSFT was performed as described before.42 In short, after food deprivation, male rats (PND 95) of group 1 were placed in one corner of an open arena (50 × 50 cm) containing clean wood chip bedding at the center of which was a filter paper containing a food pellet. The latency (s) to start an eating episode was recorded (maximum time was 900 s). After each rat, the arena was cleaned with ethanol (70%) and dried thoroughly to prevent transmission of olfactory cues.

Transcriptome sequencing
Rats within group 2 were killed at PND 128, brains were removed and stored at −80 °C. The hippocampus was dissected by punching from 300-micron frozen brain slices, and tissue from two rats was pooled for total RNA isolation and cDNA synthesis. DNA samples were prepared for RNA-seq by end repair, adaptor ligation, size selection and amplification. After quality control of DNA libraries, the samples were sequenced (36 bp, single read) with the Illumina Genome Analyzer Ix platform. Sequences were aligned to the rat rn4 reference genome50 and further analyzed using Genomatix software (www.genomatix.de). DAVID (Database for Annotation, Visualization and Integrated Discovery; http://david.abcc.ncifcrf.gov/) was used for gene ontology (GO) analysis. RNA-seq validation was performed by qRT-PCR analysis in an independent group of rats (group 1). See Supplementary Information for detailed information about the transcriptome analysis and primer sequences (Supplementary Table S1).

Quantitative reverse transcription PCR
Hippocampal tissue of rats within group 3 was crushed in liquid nitrogen. RNA was isolated (RNeasy lipid tissue kit; QIAGEN, Venlo, The Netherlands) and cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad, Veenendaal, The Netherlands) according to the manufacturer’s protocols. The qPCR reactions were performed in 7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA, USA) using the SYBR Green fluorescence quantification system (GoTaq qPCR Master Mix, Promega, Leiden, The Netherlands). See Supplementary Information for detailed information about the qRT-PCR method.

Statistical analysis
Statistical analysis of the data was carried out using the IBM Statistical Package for the Social Sciences (SPSS) version 20.0 (IBM, Armonk, NY, USA). The Shapiro–Wilks test was used to check for normal distributions. Independent samples t-tests were used for normally distributed data (corrected P-value was used when equal variance was not assumed) and Mann–Whitney U-tests for non-normal distributions. Body weight was analyzed by repeated measures analysis of variance and further analyzed per day using independent samples t-tests. Spearman correlations were performed for the correlational analysis between behavior tests and mRNA expression. Outliers (data points further than three interquartile ranges from the nearer edge of the box plot) were excluded from the analysis. Independent samples t-tests and correlations were performed two-sided. No adjustments for multiple comparison was applied for the RNA-seq. We performed qPCR validations afterwards to validate the RNA-seq results. The level of statistical significance was set at P < 0.05 in all the tests.

RESULTS

Body weight and anxiety-like behavior in response to adult fluoxetine exposure
Body weight was measured daily during the treatment period. All the rats received a daily oral administration of fluoxetine or vehicle from PND 67 to 88 (Figure 1). As shown in Figure 2a, starting weight in group 1 was not different between fluoxetine and vehicle groups (t\(_{1,22}\) = 0.26; P = 0.796). Repeated measures

![Figure 2. Fluoxetine in adult exposed Wistar rats reduces body weight and latency to start eating in a novel environment. (a) Body weight in fluoxetine- and vehicle-treated (postnatal day (PND) 67 to 88) adult male rats (n = 12/group) measured during the treatment period. Data are presented as mean ± s.e.m. of body weight (g). (b) Latency to start eating in a novel environment tested in fluoxetine- and vehicle-treated adult male rats on PND 95. Data are presented as mean±s.e.m. of latency (s) to start eating. *P < 0.05.](Image 310x137 to 542x412)
analysis of variance revealed that fluoxetine significantly reduced adult body weight gain ($F_{1,24} = 43.37; P < 0.01$). Independent samples t-tests indicated that the reduction in body weight gain was significant ($P < 0.05$) from day 4 of the treatment and further on. Vehicle-exposed rats grew on average from 295.5 g on the first day of treatment to 350.3 g on the last day of treatment, while fluoxetine-exposed rats grew on average from 294.8 g on the first day of treatment to 320.2 g on the last day of treatment (see Supplementary Table S2 for all body weight values). Similar results were obtained for group 2 (data not shown). Anxiety-like behavior was measured 1 week after treatment using the NSFT. We found that adult fluoxetine-exposed rats exhibited a shorter latency to start eating compared with vehicle-exposed animals ($t_{1,19} = 2.32; P < 0.05$; Figure 2b, Supplementary Table S2). Both decreased weight gain during chronic fluoxetine exposure$^{11}$ and a shorter latency to start eating in the NSFT after chronic fluoxetine exposure$^{64–66,72}$ are consistent with previous findings in stressed and unstressed rats.

Long-term consequences of adult chronic fluoxetine exposure on genome-wide mRNA expression patterns in the hippocampus

To investigate which genetic pathways have a role in the long-term effects of chronic SSRI exposure, RNA-seq analysis was performed using hippocampal tissue of fluoxetine- and vehicle-exposed rats (two rats pooled per sample, two samples per treatment group). Genes with a fold change $> 1.5$-fold and a $P$-value $< 0.05$ were considered as differentially regulated genes. Analysis of the samples resulted in 258 genes that were significantly upregulated and 218 genes that were significantly downregulated by fluoxetine treatment (Figure 3a, Supplementary Table S3). Some genes show overlap with a study in mice chronically treated with fluoxetine (see green marked genes in Supplementary Table S3).$^{73}$

To functionally categorize the differentially expressed genes, GO analysis was performed. The most significantly enriched GO terms in the list of upregulated genes induced by adult fluoxetine treatment are all involved in glia cell development and myelination (Table 1). Examples of upregulated genes involved in glia cell development are zinc finger protein 488 ($Znf488$), protelolipid protein 1 ($Pplp1$), ciliary neurotrophic factor ($Cntf$), NK6 homeobox 2 ($Nkx6-2$) and POU class 3 homeobox 1 ($Pou3f1$). For the genes downregulated after adult fluoxetine treatment, the most significantly enriched GO term was ‘response to abiotic (non-living) stimulus’. An underlying and more specific GO term that was also significantly enriched is ‘response to temperature stimulus (an abiotic stimulus)’, including genes such as adrenocortical beta 2 ($Adrb2$), nitric oxide synthase 1 ($NOS1$), caspase 8 ($Casp8$), transient receptor potential cation channel, subfamily V, member 3 ($Trpv3$), interleukin 1 beta ($Il1b$), chemokine (C-X-C motif) ligand 12 ($Ccl12$) and protein kinase C, delta ($Prkcd$). See Supplementary Table S4 for a complete list of significantly enriched GO terms, including the genes linked to these terms.

Validation of the adult RNA-seq data was performed by qRT-PCR analysis in independent biological replicates ($n = 11–12$ per treatment). For validation, we selected 12 differentially regulated genes (five up- and seven downregulated) on the basis of $P$-value ($P < 0.05$), fold change ($> 1.5$) and expression profile using the WIG files. Five genes, olfactomedin 1 ($Olfm1$, $U = 31.00, P < 0.05$; downregulated), adenylate cyclase 1 ($Adcy1$, $U = 33.00, P < 0.05$; downregulated), neurotensin ($Nts$, $U = 25.00, P < 0.05$; upregulated), $Cntf$ ($U = 26.00, P < 0.05$; upregulated) and claudin 11 ($Cldn11$, $U = 25.00, P < 0.05$; upregulated), showed a significant change in mRNA expression in the same direction as in the RNA-seq data (Figure 3b). Interestingly, three out of the five significantly upregulated genes in RNA-seq were significantly upregulated in qRT-PCR analysis and the other two genes also showed a change in the right direction, that is, upregulation in the fluoxetine-

Figure 3. Gene expression in adult fluoxetine-exposed male Wistar rats. (a) RNA-seq analysis was performed using hippocampal tissue of fluoxetine- and vehicle-exposed rats, two rats pooled per sample, two samples per treatment group. Fold change scatter plot showing fold change in expression (base mean) in fluoxetine-treated versus vehicle-treated (y axis) against expression level (x axis). Differentially regulated genes are genes with fold change threshold $> 1.5$ (log2 fold change $> 0.58$, blue dashed line) and $P$-value $< 0.05$ (colored in red). Red dots above the upper blue dashed line are upregulated genes (258 genes) and red dots below the lower blue dashed line are downregulated genes (218 genes). (b) Validation of RNA-seq results by quantitative RT-PCR (qRT-PCR) analysis in independent biological replicates. Quantitative RT-PCR was performed on hippocampal RNA of adult fluoxetine-treated and vehicle-treated (postnatal (PND) day 67 to 88) rats ($n = 12$ per treatment). On the basis of RNA-seq data, seven genes downregulated (left side in figure) and five genes upregulated (right side in figure) by fluoxetine exposure were selected for qRT-PCR validation. Data are normalized for Ywhaz and Hprt mRNA levels and are presented as mean±s.e.m. of relative gene expression (% of vehicle group). *$P < 0.05$ indicate genes differentially expressed in qRT-PCR. mRNA, messenger RNA.

exposed rats. However, the majority of the genes downregulated in the RNA-seq were not changed in the qRT-PCR analyses, indicating that the upregulated genes were more consistent among independent experiments. Of the upregulated genes, $Cntf$, $Cldn11$ and Tspan2 ($P = 0.17$) are involved in myelination,$^{74–76}$ indicating that myelination is one mechanism involved in the long-term effects of SSRI exposure.

Long-term consequences of neonatal chronic fluoxetine exposure on hippocampal mRNA expression

As GO analysis showed that upregulated genes are enriched for genes involved in myelination, we investigated whether
expression of myelination-related genes, we performed a correlation analysis using data (anxiety-like behavior in an open-field test (OFT, results see Boulle and colleagues) and expression analysis of myelination-related genes) derived from the neonatally fluoxetine-exposed rats (group 3). In the OFT, time spent in the corner (OFC) and time spent in the center of the open field were measured, in which OFC is a measure for anxiety-like behavior and time spent in the center of the open field is a measure for anxiolytic-like behavior. We found that OFC correlated negatively with mRNA expression of Cdn11 (r(11) = −0.736, P < 0.05), Cnp (r(11) = −0.682, P < 0.05), Plp1 (ex3−5) (r(11) = −0.827, P < 0.05) and Plp1 (ex2−3) (r(11) = −0.800, P < 0.05). In addition, Mag mRNA expression showed a trend for a negative correlation with OFC (r(11) = −0.555, P < 0.1). Finally, a trend for a positive correlation with time spent in the center of the open field was found for mRNA expression of Cdn11 (r(11) = 0.582, P < 0.1), Plp1 (ex3−5) (r(11) = 0.527, P < 0.1) and Plp1 (ex2−3) (r(11) = 0.536, P < 0.1) and Mag (r(11) = 0.573, P < 0.1). See Supplementary Figure S1−S3 for a complete overview of the correlation data.

Taken together, these data indicate that a higher expression of myelination-related genes is linked to anxiolytic-like behavior in both the NSFT in adult fluoxetine-exposed rats and the OFT in the neonatally fluoxetine-exposed rats.

**DISCUSSION**

In this study, we demonstrate, using a genome-wide approach, that 40 days after chronic fluoxetine treatment in adult rats mRNA levels of myelination-related genes were significantly upregulated in the hippocampus. Interestingly, in an independent group of rats, we observed that chronic neonatal fluoxetine exposure downregulated myelination-related genes. We specifically observed that the myelination-related Cntf gene was upregulated in adult fluoxetine-exposed rats and downregulated in neonatally fluoxetine-exposed rats. In addition, we observed a negative correlation between expression of myelination-related genes and anxiety-like behavior in both the adult and neonatally fluoxetine-exposed rats. These data suggest that chronic SSRI exposure...
Interestingly, we did not find an overlap in differentially regulated genes between studies focusing on short-term effects and our study about long-term effects. For instance, Samuels et al. performed a microarray study using dantane gyrus tissue from 24 h after treatment cessation of adult mice chronically treated with fluoxetine and identified eight upregulated and 20 downregulated genes that overlap with our findings (see green marked genes in Supplementary Table S3). Genes affected in both short- and long-term studies might have a crucial role in inducing and maintaining the antidepressant state. It is not likely that effects of fluoxetine withdrawal are seen in our expression data, because these effects occur shortly after withdrawal and will not last for 40 days.

RNA-seq validation by qPCR showed that the upregulated genes were more consistent among independent experiments. We were unable to validate five out of the seven downregulated genes, therefore, we focused on the upregulated genes. The GO analysis of genes upregulated by chronic fluoxetine exposure in adulthood revealed that the majority of these genes have a function in myelination. In addition, we found a correlation between the latency to start eating in the SSRI-sensitive NSFT and gene expression of myelination-related genes (Cntd11, and a trend for Tspan2), which strengthens our findings. Interestingly, a wide range of psychiatric disorders responsive to SSRI treatment, including depression, bipolar affective disorder, obsessive compulsive disorder, post-traumatic stress disorder and autism spectrum disorder have been associated with defects in white matter, which consists mainly of myelinated axons. A first link between mood disorders and myelin was shown by Aston et al. They studied gene expression in the temporal cortex of major depressive disorder patients and found a decreased expression of genes encoding structural components of myelin (for example, 2',3'-cyclic nucleotide 3' phosphodiesterase (CNP), myelin-associated glycoprotein (MAG), myelin oligodendrocyte glycoprotein (MOG), PLP1) and genes involved in myelin formation (for example, TF, SRY (sex determining region Y)-box 10 (SOX10)). We showed in our RNA-seq experiment that the SSRI-sensitive fluoxetine increases the expression of genes linked to myelination in the hippocampus. Interestingly, we did not find the same genes as Aston et al. found in the temporal cortex (gene expression might be brain region dependent), but we did find genes (Cntf, Cldn11) influencing the same process. Genes interacting with each other (SOX10 and Cntf) and genes with similar functions regarding myelination (PLP1 and Cldn11) were identified by a group that focused on high levels of ciliary neurotrophic factor (CNTF) gene and anxiety correlated negatively in both the adult and neonatally fluoxetine-exposed rats does not support this. Given that changes in myelination have been reported by others after both neonatal and adult SSRI exposure, it is more likely that our findings are the result of fluoxetine exposure at different ages. The Cntf gene, coding for ciliary neurotrophic factor, is the only gene differentially regulated in all our experimental groups. CNTF is a neurotrophic factor produced by astrocytes, which supports the proliferation and survival of oligodendrocyte precursors and regulates myelination. Studies have shown that CNTF can mediate stroke-induced adult central nervous system neurogenesis and that CNTF injection can increase remyelination in cuprizone-induced multiple sclerosis mice, supporting the role of CNTF as a neurotrophic factor and as a myelin regulator. In the hippocampus, Cntf is strongest expressed in the dentate gyrus and CA1 regions. The dentate gyrus is important for adult neurogenesis and therefore Cntf expression in this region fits well with its role in neurogenesis. Studies have shown that CNTF is essential for the formation and/or maintenance of the neurogenic subgranular zone in the adult dentate gyrus. How fluoxetine targets myelination-related genes is still unclear. On the basis of literature, we propose a potential pathway, but this is highly speculative (see Supplementary Figure S4). In short, fluoxetine stimulates the S-HT2B receptor on astrocytes resulting in activation of its downstream signaling cascades, which potentially can lead to release of CNTF. The released CNTF can activate astrocytes and these astrocytes then release an astrocyte-derived factor (>30 kDa), which promotes proliferation and survival of oligodendrocyte precursor cells and maturation of oligodendrocytes. Of further interest, Cntf –/– mice display increased anxiety- and depression-like behavior. These findings are in line with the reduced Cntf expression that we found in the group of rats exposed to fluoxetine at early life, which also showed increased depression-like behavior. Cldn11 expression is upregulated by adult chronic fluoxetine exposure and showed a negative correlation with anxiety-like behavior in the NSFT. In the neonatally fluoxetine-exposed rats, Cldn11 expression also showed a negative correlation with anxiety-like behavior (OFc) in the OFT, despite the absence of significant differences between the treatment groups in the OFT and the expression analysis. Cldn11 codes for Claudin-11, which is a major component of myelin and
forms tight junctions within myelin sheaths. Downregulation of Cldn11 has been found in bipolar affective disorder patients. Also Ptp1 and Cnp showed a negative correlation with anxiety-like behavior (OFC) in the OFT. Taken together, the correlations indicate that a higher expression of myelination-related genes results in anxiety-like behavior.

In this study, we found that fluoxetine can cause long-term changes in the expression of myelination-related genes. However, a potential limitation of the present study is that we used a homogenate of hippocampus cells and there are different cell types in the hippocampus tissue. Selecting a specific cell type using fluorescence-activated cell sorting might give more insights in the gene expression per cell type, although it is notable that mRNA levels correlated with behavior. Another limitation of this study is that the fluoxetine dose differs between the perinatal (5 mg kg$^{-1}$ per day) and adult (12 mg kg$^{-1}$ per day) exposed groups. However, studies have shown that exposure to higher doses of fluoxetine early in life (10–20 mg kg$^{-1}$ per day) affects anxiety-like behavior (for example, OFT) in the same way as seen for 5 mg kg$^{-1}$.

Furthermore, studies using a lower dose of fluoxetine in adulthood (5 mg kg$^{-1}$ per day) showed a similar effect on anxiety-like behavior in the NSFT as shown in this study for 12 mg kg$^{-1}$ per day.65 In the future, it is relevant to explore whether fluoxetine exposure will give similar results in models for psychiatric disorders responsive to SSRIs. Given that the effect of SSRIs in the NSFT is the same in healthy,64,65 and stressed66,72 animals it is likely that also gene expression patterns will be similar. Finally, we measured gene expression, and it remains to be established whether our findings translate to changes in protein levels and myelination. As a next step in biology, evidence of changes in myelination will further support our findings. As such, it has already been demonstrated that SSRI treatment can have consequences for myelination.60,63,104

In conclusion, we show that adult and neonatal chronic fluoxetine exposure cause long-term changes in hippocampal expression of ciliary neurotrophic factor and other genes linked to myelination, a process that shapes brain connectivity and could contribute to the remediation of symptoms of psychiatric disorders, like anxiety.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank Professor H Stunnenberg for providing the sequencing facility for RNA-seq analysis; E Janssens-Megers, K Berentsen and KJ Françoys for operating the Illumina Genome Analyzer and initial data output; and S Van Heeringen for discussions about data analysis. This work has been funded by the Donders Centre for Neuroscience and the Dutch Brain Foundation (2013(1)-24). These funding sources had no role in data acquisition and manuscript writing.

REFERENCES

1 Olivier JD, Blom T, Arendsen T, Homberg JR. The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1400–1408.
2 Cipriani A, Brambilla P, Furukawa T, Geddes J, Gregis M, Hotopf M et al. Fluoxetine versus other types of pharmacotherapy for depression. Cochrane Database Syst Rev 2005; CD004185.
3 Cristancho MA, Thase ME. Drug safety evaluation of olanzapine/fluoxetine combination. Expert Opin Drug Saf 2014; 13: 1133–1141.
4 Pittenger C, Bloch MH. Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am 2014; 37: 375–391.
5 Koen N, Stein DJ. Pharmacotherapy of anxiety disorders: a critical review. Dialogues Clin Neurosci 2011; 13: 423–437.
6 Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997; 54: 1081–1088.

7 Doyle CA, McDougle CJ. Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 2012; 14: 263–279.
8 Makkonen I, Kokki H, Kuikka J, Turpeinen U, Riikonen R. Effects of fluoxetine treatment on striatal dopamine transporter binding and cerebrospinal fluid insulin-like growth factor-I in children with autism. Neuropsychiatrics 2011; 42: 207–209.
9 Khazaie H, Rezaei L, Rezaei Payam N, Najafi F. Antidepressant-induced sexual dysfunction during treatment with fluoxetine, sertraline and trazodone: a randomized controlled trial. Gen Hosp Psychiatry 2015; 37: 40–45.
10 Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005; 20: 533–559.
11 Zou C, Ding X, Flaherty JH, Dong B. Clinical efficacy and safety of fluoxetine in generalized anxiety disorder in Chinese patients. Neuropsychiatr Dis Treat 2013; 9: 1661–1670.
12 Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 2014; 29: 185–196.
13 Wagtstaff AJ, Cheer SM, Matheson AJ, Omrdom D, Gao KL. Spotlight on paroxetine in psychiatric disorders in adults. CNS Drugs 2002; 16: 425–434.
14 Okada F, Okajima K. Violent acts associated with fluoxetine treatment. J Psychiatry Neurosci 2001; 26: 339–340.
15 Healy D, Herzheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS Med 2006; 3: e372.
16 Shelton RC. Steps following attainment of remission: discontinuation of antidepressant treatment. Prim Care Companion J Clin Psychiatry 2001; 3: 168–174.
17 Altschuler L, Suppes T, Black D, Nolen WA, Keck PE Jr, Frye MA et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160: 1252–1262.
18 Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270–1278.
19 Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002; 59: 1111–1118.
20 Flint AJ, Rifat SL. Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 1999; 156: 943–945.
21 Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509–522.
22 Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mark A et al. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology 2004; 29: 1782–1789.
23 Cremers TI, Rea K, Bosker FJ, Wikstrom HV, Hogg S, Mark A et al. Augmentation of SSRI effects on serotonin by 5-HT2C antagonists: mechanistic studies. Neuropsychopharmacology 2007; 32: 1550–1557.
24 Yamada J, Sugimoto Y. Effects of 5-HT(2C) receptor antagonists on the anti-immobility effects of imipramine in the forced swimming test with mice. Eur J Pharmacol 2001; 427: 221–225.
25 Minie-Filali O, Lambas-Senas L, Zimmer L, Haddjeri N. 5-HT7 receptor antagonists as a new class of antidepressants. Drug News Perspect 2007; 20: 613–618.
26 Artiga F, Romero L, de Montigny C, Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 1996; 19: 378–383.
27 Portella MM, de Diego-Adelino J, Ballestros J, Puigdemont D, Oller S, Santos B et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011; 72: 962–969.
28 Guptarak J, Sarkar J, Hiegel C, Uphouse L. Role of 5-HT1A receptors in fluoxetine-induced lordosis inhibition. Horm Behav 2010; 58: 290–296.
29 Shelton J, Bonaventure P, Li X, Yun S, Lovendeg L, Dugovic C. 5-HT7 receptor deletion enhances REM sleep suppression induced by selective serotonin reuptake inhibitors, but not by direct stimulation of 5-HT1A receptor. Neuropharmacology 2009; 56: 448–454.
30 Monaca C, Boustel B, Hen R, Hamon M, Adrien J. 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 2003; 28: 381–386.
31 Tanaka M, Kobayashi D, Murakami Y, Ozaki N, Suzuki T, Iwata N et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11: 261–267.
32 Nonogaki K, Ohba Y, Wakameda M, Tamari T. Fluvoxamine exerts anorexic effect in 5-HT2C receptor mutant mice with heterozygous mutation of beta-endorphin gene. Int J Neuropsychopharmacol 2009; 12: 547–552.
Front Cell Neurosci 7: 1002–1012.

Riccio O, Potter G, Walzer C, Vallet P, Szabó G, Vutsiskis L et al. Excess of serotonin affects embryonic interneuron migration through activation of the serotonin receptor 6. Mol Psychiatry 2009; 14: 280–290.

Miceli S, Negrer M, van Eijs F, Kalkhoven C, van Lierop I, Homberg J et al. Adipose tissue-specific overexpression of S-HT1A receptor alters cardiovascular functions in unanesthetized rats. Eur J Pharmacol 2011; 670: 527–533.

Gregoire BN, Andreazza AC, Nery FG, Martins MR, Quevedo J, Soares JC et al. The role of hippocampus in avoidance learning and anxiety vulnerability. Front Behav Neurosci 2014; 8: 273.

Frey BN, Andreazza AC, Nery FG, Martins MR, Quevedo J, Soares JC et al. The role of hippocampus in the pathophysiology of bipolar disorder. Behav Pharmacol 2007; 18: 419–430.

Zetzsche T, Preuss UW, Frodl T, Schmitt G, Seifert D, Munchhausen E et al. Hippocampal volume reduction and history of aggressive behaviour in patients with borderline personality disorder. Psychiatry Res 2007; 154: 157–170.

Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 2004; 29: 417–426.

Homberg JR, Olivier JD, Blom T, Arentsen T, van BC, Schipper P et al. Fluoxetine exerts age-dependent effects on behavior and amygdala plasticity in the rat. PLoS One 2011; 3: e16466.

Thompson MR, Li KM, Clemens KJ, Gurtman CG, Hunt GE, Cornish JL et al. Chronic fluoxetine treatment partially attenuates the long-term anxiety and depressive symptoms induced by MDMA (‘Ecstasy’) in rats. Neuropsychopharmacology 2004; 29: 694–704.

Miyamoto D, Iijima M, Yamamoto H, Nomura H, Matsuji N. Behavioural effects of antidepressants are dependent and independent on the integrity of the dentate gyrus. Int J Neuropsychopharmacol 2011; 14: 967–976.

Eitan R, Landshut G, Lifschytz T, Einstein O, Ben-Hur T, Lerer B. The thyroid hormone, triiodothyronine, enhances fluoxetine-induced neurogenesis in rats: possible role in antidepressant-enhancing properties. Int J Neuropsychopharmacol 2010; 13: 553–555.

Zhu Z, Yan HY, Zhou Y, Jia Q, Qu HD, Xu QS, Chen L et al. Intermittent hypoxia promotes hippocampal neurogenesis and produces antidepressant-like effects in adults. J Neurosci 2010; 30: 12653–12663.

Shan L, Schiper P, Nonkes L, Homberg JR. Impaired fear extinction as displayed by serotonin transporter knockout rats housed in open cages is disrupted by IVC cage housing. PLoS One 2014; 9: e91472.

Schiper P, Nonkes LJ, Karel P, Kiliaan AJ, Homberg JR. Serotonin transporter genotype x construction stress interaction in rats. Behav Brain Res 2011; 223: 169–175.

Pawluski JL, Rajay J, Niessen NA, Kristensen S, van Donkelaar EL, Balthazart J et al. Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience 2012; 220: 131–141.

Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Gorshen S et al. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 2004; 428: 493–521.

Crestani CC, Tavares RF, Guimaraes FS, Correa FM, Joca SR, Resstel LB. Chronic fluoxetine treatment alters cardiovascular functions in unanesthetized rats. Eur J Pharmacol 2011; 670: 527–533.

Greene J, Bansa M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology 2009; 34: 2459–2468.

Samuels BA, Leonardo ED, Dranovsky A, Williams A, Wong E, Nesbitt AM et al. Global state measures of the dentate gyrus gene expression system predict antidepressant-sensitive behaviors. PLoS One 2014; 9: e95316.

Moore CS, Abdallah SL, Brown A, Arulpragasam A, Crocker SJ. How factors secreted from astrocytes impact myelin repair. J Neurosci Res 2011; 89: 13–21.

Bronstein JM. Function of tetraxapins proteins in the myelin sheath. Curr Opin Neurobiol 2000; 10: 552–557.

Brilmg MC, Tait S, Hardy RJ, Brophy PJ. A novel rat tetraspan protein in cells of the oligodendrocyte lineage. J Neurochem 1999; 73: 2600–2608.

Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry 2005; 10: 309–322.

Bouille F, Pawluski JL, Homberg JR, Machiefs B, Kroeze Y, Kumar N et al. Developmental fluoxetine exposure increases depressive-like behavior and alters epigenetic regulation of the hippocampal BDNF gene in prenatally stressed female offspring. Submitted.

Junge P, Ostrow G, Li JL, Norton S, Nieber K, Kelber O et al. Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John’s wort extract (STW 3-VI) and fluoxetine. Psychopharmacology (Berl) 2011; 213: 757–772.

Lee JH, Ko E, Kim YE, Min JY, Liu J, Kim Y et al. Gene expression profile analysis of genes in rat hippocampus following antidepressant treated rats using DNA micro-array. BMC Neurosci 2010; 11: 52.

O’Connor RM, Grenham S, Dinan TG, Cryan JF. microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. J Neuropsychopharmacology 2013; 16: 1885–1892.
Fluoxetine targets myelination-related genes
Y Kroeze et al

82 Deoni SC, Zinkstok JR, Daly E, Ecker C, Consortium MA, Williams SC et al. White matter relaxation time and myelin water fraction differences in young adults with autism. *Psychol Med* 2015; 45: 795–805.

83 Fields RD. White matter in learning, cognition and psychiatric disorders. *Trends Neurosci* 2008; 31: 361–370.

84 Ito Y, Wiese S, Funk N, Chittka A, Rossoli W, Bommel H et al. Sox10 regulates ciliary neurotrophic factor gene expression in Schwann cells. *Proc Natl Acad Sci USA* 2006; 103: 7871–7876.

85 Chow E, Mottahedeh J, Prins M, Ridder W, Nusinowitz S, Bronstein JM. Disrupted compaction of CNS myelin in an OSP/Claudivin-11 and PLP/DM20 double knockout mouse. *Mol Cell Neurosci* 2005; 29: 405–413.

86 De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. *Neuroscience* 2004; 128: 597–604.

87 Fan LW, Bhatt A, Tien LT, Zheng B, Simpson KL, Lin RC et al. Exposure to serotonin adversely affects oligodendrocyte development and myelination in vitro. *J Neurochem* 2014; 133: 532–543.

88 Barres BA, Burne JF, Holtmann B, Thoenen H, Sendtner M, Raff MC. Ciliary neurotrophic factor enhances the rate of oligodendrocyte generation. *Mol Cell Neurosci* 1996; 8: 146–156.

89 Louis JC, Magal E, Takayama S, Varon S. CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death. *Science* 1993; 259: 689–692.

90 Mayer M, Bhakoo K, Noble M. Ciliary neurotrophic factor and leukemia inhibitory factor promote the generation, maturation and survival of oligodendrocytes in vitro. *Development* 1994; 120: 143–153.

91 Yokota H, Yoshikawa M, Hirabayashi H, Nakase H, Uranishi R, Nishimura F et al. Expression of ciliary neurotrophic factor (CNTF), CNTF receptor alpha (CNTFR-alpha) following experimental intracerebral hemorrhage in rats. *Neurosci Lett* 2005; 377: 170–175.

92 Kang SS, Keaspy MP, Arnold SA, Reid R, Geralds J, Hagg T. Endogenous CNTF mediates stroke-induced adult CNS neurogenesis in mice. *Neurobiol Dis* 2012; 49C: 68–78.

93 Salehi Z, Hadiyan SP, Navidi R. Ciliary neurotrophic factor role in myelin oligodendrocyte glycoprotein expression in Cuprizone-induced multiple sclerosis mice. *Cell Mol Neurobiol* 2013; 33: 531–535.

94 Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A et al. Genome-wide atlas of gene expression in the adult mouse brain. *Nature* 2007; 445: 168–176.

95 Muller S, Chakrapani BP, Schwergler H, Hofmann HD, Kirsch M. Neurogenesis in the dentate gyrus depends on ciliary neurotrophic factor and signal transducer and activator of transcription 3 signaling. *Stem Cells* 2009; 27: 431–441.

96 Hertz L, Rothman DL, Li B, Peng L. Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glucose, glutamate and glycogen: a potential paradigm shift. *Front Behav Neurosci* 2015; 9: 25.

97 Albrecht PJ, Enterline JC, Cromer J, Levison SW. CNTF-activated astrocytes release a soluble trophic activity for oligodendrocyte progenitors. *Neurochem Res* 2007; 32: 263–271.

98 Stankoff B, Aigrot MS, Noel F, Wattilliaux A, Zalc B, Lubetzki C. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. *J Neurosci* 2002; 22: 9221–9227.

99 Peruga L, Hartwig S, Merkler D, Thone J, Hovemann B, Juckel G et al. Endogenous ciliary neurotrophic factor modulates anxiety and depressive-like behavior. *Behav Brain Res* 2012; 229: 325–332.

100 Morita K, Sasaki H, Fujimoto K, Furuse M, Tsukita S. Claudin-11/OSP-based tight junctions of myelin sheaths in brain and Sertoli cells in testis. *J Cell Biol* 1999; 145: 579–588.

101 Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. *Lancet* 2003; 362: 798–805.

102 Karpova NN, Lindholm J, Pruunsild P, Timmusk T, Castren E. Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. *Eur Neuropsychopharmacol* 2009; 19: 97–108.

103 Ko MC, Lee LJ, Li Y, Lee LJ. Long-term consequences of neonatal fluoxetine exposure in adult rats. *Dev Neurobiol* 2014; 74: 1038–1051.

104 Yune TY, Lee JY, Kang S. Fluoxetine prevents oligodendrocyte cell death by inhibiting microglia activation after spinal cord injury. *J Neurotrauma* 2015; 32: 633–644.

Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)